Company Control Change - *ST Ningke has experienced a significant stock price increase, achieving five consecutive trading limits. The company is currently in the execution phase of its restructuring plan [1][3] - The company announced that its controlling shareholder and actual controller will change, with Liu Xirong becoming the new actual controller [1][3] - On December 16, the company disclosed that 882 million shares, accounting for 54.64% of the total share capital, were transferred from the management's securities account to the designated securities account of the restructuring investor [1][3] Financial Misrepresentation - In 2022, the company inflated its operating revenue by 76.5941 million yuan and its total profit by 77.222 million yuan, representing 11.25% and 46.59% of the respective figures for that period [1][3] - The company failed to disclose significant events in a timely manner, particularly regarding major debts and the suspension of key business operations of its subsidiaries [1][3] Investor Compensation - The successful restructuring of *ST Ningke is expected to benefit investor compensation efforts. The restructuring plan is set to be executed until December 31, 2025 [2][4] - Investors who meet specific criteria can actively participate in compensation registration to recover losses incurred due to the company's financial misrepresentation [2][4] - Legal representation by experienced lawyers, such as Liu Peng, is emphasized as crucial for maximizing investor rights and compensation outcomes [2][4]

*ST中装公告称，2025年12月18日，公司收到深圳中院送达的《民事裁定书》，其裁定批准公司重整计 划，并终止重整程序。此前，12月16日，公司第二次债权人会议和出资人组会议已分别表决通过重整计 划草案及出资人权益调整方案。法院裁定批准后，公司将进入执行阶段，若执行完毕，利于优化资产负 债结构等，但公司股票已被实施退市及其他风险警示，后续仍存重整失败、股价除权调整等风险。 ...

债务清偿方面，职工债权与税款债权将在重整计划获批后3个月内现金全额清偿；有财产担保债权在担 保财产价值范围内优先现金清偿；普通债权则分档处理，300万元以下部分获现金与股票组合清偿，300 万元以上部分以股票加信托受益权份额抵偿。 同时，公司将通过设立服务信托剥离低效资产，聚焦医美与生物基纤维主业。重整完成后，产业投资人 九州通将发挥医药大健康领域资源优势，助力奥园美谷优化治理、拓展产业链，公司拟通过精细化管 理、资产并购等提升盈利能力。 南方财经12月18日电，*ST美谷(000615.SZ)12月18日公布重整计划，旨在化解债务危机并避免退市风 险，该计划由襄阳市中级人民法院裁定批准。 奥园美谷近年受化纤板块亏损、控股股东债务危机等影响，陷入流动性困境，2025年4月起被实施退市 风险警示。此次重整以7.63亿股总股本为基数，按每10股转增13.43股的比例，共计转增10.25亿股，转 增后总股本将增至17.87亿股。转增股票中，约7630万股向部分股东分配，其余9.48亿股用于引入重整投 资人和抵偿债务。九州产投、信美通成及6家财务投资人组成的重整投资团，将以15.36亿元认购8.62亿 股，其中1.4 ...

*ST美谷公告称，12月16日晚公司收到襄阳中院送达的《民事裁定书》，法院裁定批准《奥园美谷科技 股份有限公司重整计划》并终止公司重整程序。此前，11月14日法院裁定受理债权人对公司的重整申请 并指定管理人；12月15日，债权人会议和出资人组会议均表决通过相关方案。裁定批准后，公司将进入 重整计划执行阶段，若顺利执行完毕，将改善公司状况，对2025年度财务指标产生重大影响。不过，公 司仍面临破产、终止上市及协议履约等风险。 ...

Core Viewpoint - The article discusses the regulatory actions against Renfu Pharmaceutical and its former controlling shareholder, Dongdai Group, highlighting significant financial misconduct and the subsequent restructuring of the company under new control. Group 1: Regulatory Actions and Violations - Renfu Pharmaceutical was officially designated as ST (Special Treatment) on December 16 due to multiple violations, including significant fund occupation and false financial reporting [1][3] - The Hubei Securities Regulatory Bureau issued a notice detailing four main violations from 2020 to 2022, including a total fund occupation of 12.785 billion yuan, which represented a significant percentage of the company's net assets during those years [5][6] - The total fines imposed on Renfu Pharmaceutical and Dongdai Group amounted to 36.7 million yuan, with individual penalties for responsible parties ranging from 500,000 to 3.9 million yuan [8] Group 2: Financial Misconduct Details - The first violation involved non-operational fund occupation, with Dongdai Group occupying 2.502 billion yuan, 8.179 billion yuan, and 2.104 billion yuan in 2020, 2021, and early 2022, respectively [5] - The second violation related to undisclosed related-party transactions, where Renfu Pharmaceutical purchased assets from a company closely related to Dongdai Group without proper disclosure, totaling 1.645 billion yuan [6] - The third violation included false financial records, where Renfu Pharmaceutical inflated its net profit by 143 million yuan, 72 million yuan, and 91 million yuan in 2020, 2021, and the first half of 2022, respectively [6] - The fourth violation involved the concealment of related-party relationships during a transaction, leading to a lack of timely disclosure [7] Group 3: Corporate Restructuring and New Control - Following the financial misconduct, Renfu Pharmaceutical's control was transferred to China Merchants Group, which invested 11.8 billion yuan to acquire a 23.70% voting stake in the company [9][10] - The restructuring process was initiated due to Dongdai Group's severe debt crisis, which included bankruptcy proceedings initiated by creditors [9] - Significant changes in the board and management of Renfu Pharmaceutical occurred post-restructuring, with new appointments from China Merchants Group [10] Group 4: Financial Performance - For the first three quarters of 2025, Renfu Pharmaceutical reported revenues of 17.883 billion yuan, a decrease of 6.58% year-on-year, while net profit attributable to shareholders increased by 6.22% to 1.689 billion yuan [11]

*ST中装公告称，2025年12月16日，公司第二次债权人会议召开，表决通过《深圳市中装建设集团股份 有限公司重整计划（草案）》。有财产担保债权组、劳务债权组、普通债权组均表决通过该草案。不 过，《重整计划（草案）》尚未获深圳中院裁定批准，存在不确定性。公司股票已被实施退市风险警 示，若重整失败被宣告破产，股票将面临终止上市风险。此外，公司股票还存在其他风险警示。 ...

*ST张股公告，公司及全资子公司张家界大庸古城发展有限公司的重整计划已获湖南省张家界市中级人 民法院裁定批准，并终止重整程序。公司将进入重整计划执行阶段，若顺利执行，将改善资产负债结构 及经营状况，提升持续经营和盈利能力，对2025年度财务指标产生积极影响。 ...

Core Viewpoint - The company *ST Muban announced that its stock experienced an abnormal fluctuation with a cumulative closing price drop exceeding 12% over three consecutive trading days from December 12 to 16, 2025, indicating significant uncertainty regarding its potential restructuring process [1] Financial Performance - For the period of January to September 2025, the company reported revenue of 226.82 million yuan and a net loss of 355.72 million yuan [1] - If the annual revenue for 2025 falls below 300 million yuan, the company's stock will be delisted following the annual report disclosure [1] Legal and Operational Status - The company and its actual controller, Liao Zhiyuan, are under investigation [1] - Despite the ongoing issues, the company stated that its production and operations are currently normal [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000430 证券简称：*ST张股 公告编号：2025-065 张家界旅游集团股份有限公司 出资人组会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 特别提示 1.本次出资人组会议不存在否决议案的情形。 2.本次出资人组会议不涉及变更以往股东会已通过的决议。 3.本次出资人组会议表决通过了《张家界旅游集团股份有限公司及其子公司重整计划（草案）之出资人 权益调整方案》。 一、会议召开和出席情况 （一）会议召开情况 6.本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第14 号一一破产重整等事项》《深圳证券交易所主板股票上市规则》等有关法律、行政法规、部门规章、规 范性文件和《公司章程》的有关规定。 （二）会议出席情况 1.出席会议的总体情况 1.会议召开的日期、时间： 现场会议时间为：2025年12月15日上午09:00 网络投票时间为：2025年12月15日 其中，通过深圳证券交易所系统进行网络投票的具体时间为9:15-9:25，9:30-11:30， ...

*ST炼石公告称，2025年12月12日收到成都中院裁定，终结公司重整程序，截至公告披露日，重整计划 已执行完毕。公司于6月启动预重整，9月重整申请获受理，10月重整计划草案通过，11月转增5.23亿股 股票已完成。重整后公司化解债务危机，改善资产负债结构，将推动存量与增量业务发展，预计对2025 年财务状况产生积极影响。公司将申请撤销退市风险警示，结果尚不确定。 ...